

according to the Globally Harmonized System

Ribavirin Liquid Formulation

Version 2.8	Revision Date: 30.09.2023		S Number: 3975-00018	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
1. PRODU	JCT AND COMPANY ID	ENI	IFICATION	
Produ	uct name	:	Ribavirin Liqu	id Formulation
Manı Com	ufacturer or supplier's c pany		ils MSD	
Addre	Address			Off Pune Nagar Road ne - India 412 207
Telep	Telephone		+1-908-740-4	000
Emer	Emergency telephone number		+1-908-423-6	000
E-ma	E-mail address		EHSDATAST	EWARD@msd.com
Deee	mmandad usa of the al	h o m	ical and reatri	ations on uso

Recommended use of the chemical and restrictions on use

Recommended use	:	Pharmaceutical
Restrictions on use	:	Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification		
Germ cell mutagenicity	:	Category 2
Reproductive toxicity	:	Category 1B
Specific target organ toxicity - repeated exposure (Oral)	:	Category 2 (Blood)
GHS label elements		
Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H341 Suspected of causing genetic defects.H360Df May damage the unborn child. Suspected of damaging fertility.H373 May cause damage to organs (Blood) through prolonged

or repeated exposure if swallowed.

according to the Globally Harmonized System



>= 30 - < 50

>= 1 - < 5

Ribavirin Liquid Formulation

Version 2.8	Revision Date: 30.09.2023	SDS Number: 406975-00018	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
Preca	autionary statements	P260 Do not b	read and follow all safety instructions before use. breathe mist or vapours. rotective gloves/ protective clothing/ eye protec- ection.
		Response: P318 IF expos	sed or concerned, get medical advice.
		Storage:	akad up

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	:	Mixture		
Components				
Chemical name			CAS-No.	Concentration (% w/w)

57-50-1

36791-04-5

4. FIRST AID MEASURES

Sucrose

Ribavirin

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Suspected of causing genetic defects. May damage the unborn child. Suspected of damaging fertili- ty. May cause damage to organs through prolonged or repeated



according to the Globally Harmonized System

Ribavirin Liquid Formulation

Vers 2.8	ion	Revision Date: 30.09.2023		DS Number: 6975-00018	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
Protection of first-aiders Notes to physician		:	exposure if swallowed. First Aid responders should pay attention to self-protection and use the recommended personal protective equipment when the potential for exposure exists (see section 8). Treat symptomatically and supportively.		
5. FI	REFIG	HTING MEASURES			
	Suitabl	e extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical	
	Unsuita media	able extinguishing	:	None known.	
	Specifi fighting	c hazards during fire-	:	Exposure to com	pustion products may be a hazard to health.
		dous combustion prod-	:	Carbon oxides	
	Specifi ods	c extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
		l protective equipment fighters	:	In the event of fire	e, wear self-contained breathing apparatus. tective equipment.
6. A0	CCIDE	NTAL RELEASE MEA	SUF	RES	
	tive eq	nal precautions, protec- uipment and emer- procedures	:	Follow safe hand	tective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8).

gene) precedence		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide dyking or other appropriate contain- ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor- bent. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

according to the Globally Harmonized System



Ribavirin Liquid Formulation

Version 2.8	Revision Date: 30.09.2023	SDS Number: 406975-00018	
7. HANDI	ING AND STORAGE		
Tech	nical measures		eering measures under EXPOSURE _S/PERSONAL PROTECTION section.
Local/Total ventilation			t ventilation is unavailable, use with local exhaust
Advie	ce on safe handling	: Do not get Do not bre Do not sw Avoid cont Wash skin Handle in practice, b sessment Keep cont Do not eat	on skin or clothing. athe mist or vapours. allow. act with eyes. thoroughly after handling. accordance with good industrial hygiene and safety ased on the results of the workplace exposure as- ainer tightly closed. , drink or smoke when using this product. to prevent spills, waste and minimize release to the
Cond	litions for safe storage	Store lock Keep tight	ly closed.
Mate	rials to avoid	: Do not sto	cordance with the particular national regulations. re with the following product types: dizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Sucrose	57-50-1	TWA	10 mg/m3	ACGIH
Ribavirin	36791-04-5	Wipe limit	400 µg/100 cm ²	Internal
		TWA	40 µg/m3 (OEB 3)	Internal

Engineering measures :	Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.
Personal protective equipment	
Respiratory protection :	If adequate local exhaust ventilation is not available or expo-

Respiratory protection		If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec-
		ommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapour type

according to the Globally Harmonized System



Ribavirin Liquid Formulation

Version 2.8	Revision Date: 30.09.2023	SDS Number: 406975-00018	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015				
Hand	l protection						
Material		: Chemical-resistant gloves					
Remarks Eye protection		: Wear safety g If the work en mists or aeros Wear a faces	 Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols 				
Skin and body protection		Additional boo being perform suits) to avoid Use appropria	 Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing. 				
Hygie	ene measures	: If exposure to flushing syste place. When using o Wash contam The effective engineering o appropriate d industrial hyg	chemical is likely during typical use, provide eye ems and safety showers close to the working lo not eat, drink or smoke. inated clothing before re-use. operation of a facility should include review of ontrols, proper personal protective equipment, egowning and decontamination procedures, iene monitoring, medical surveillance and the strative controls.				

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	liquid
Colour	:	clear
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	4.8 - 5.5
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available

according to the Globally Harmonized System



Ribavirin Liquid Formulation

Ver 2.8	sion	Revision Date: 30.09.2023		S Number: 975-00018	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
	Lower explosion limit / Lower flammability limit		:	No data available	•
	Vapour pressure		:	No data available)
	Relative	e vapour density	:	No data available)
	Relative	e density	:	No data available)
	Density	,	:	No data available)
	Solubili Wat	ty(ies) er solubility	:	No data available	9
	Partitio octanol	n coefficient: n-	:	Not applicable	
		nition temperature	:	No data available	9
	Decomposition temperature		:	No data available	9
	Viscosi Visc	ty cosity, kinematic	:	No data available	9
	Explosi	ve properties	:	Not explosive	
	Oxidiziı	ng properties	:	The substance of	mixture is not classified as oxidizing.
	Particle	e size	:	Not applicable	

10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	: : :	Not classified as a reactivity hazard. Stable under normal conditions. Can react with strong oxidizing agents.
Conditions to avoid Incompatible materials Hazardous decomposition products		None known. Oxidizing agents No hazardous decomposition products are known.


11. TOXICOLOGICAL INFORMATION

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

Acute toxicity

Not classified based on available information.

Product:





rsion	Revision Date: 30.09.2023	-	S Number: 6975-00018	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
۸ o.u				motor > E 000 mg/kg
Acu	te oral toxicity	:	Method: Calculatio	mate: > 5,000 mg/kg on method
<u>Con</u>	nponents:			
Suc	rose:			
Acu	te oral toxicity	:	LD50 (Rat): 29,70	0 mg/kg
	avirin:			
Acu	te oral toxicity	:	LD50 (Rat): 4,116	5 - 5,584 mg/kg
			LD50 (Mouse): > 7	10,000 mg/kg
			LD50 (Dog): >= 1,	500 mg/kg
Acu	te inhalation toxicity	:	Remarks: No data	a available
Acu	te dermal toxicity	:	Remarks: No data	a available
	te toxicity (other routes of iinistration)	:	LD50 (Rat): 1,554 Application Route	
			LD50 (Mouse): 1,2 Application Route	
Skir	n corrosion/irritation			
	classified based on availa	ble	information.	
	nponents:			
	avirin: narks	:	No data available	
Ron		•	May irritate skin.	
Seri	ious eye damage/eye irri	tati	on	
Not	classified based on availa	ble	information.	
Con	nponents:			
Riba	avirin:			
Ren	narks	:	No data available May irritate eyes.	
Res	piratory or skin sensitis	atio	n	
Skir	n sensitisation			
Not	classified based on availa	ble	information.	
	piratory sensitisation classified based on availa	ble	information.	



according to the Globally Harmonized System

ersion B	Revision Date: 30.09.2023		8 Number: 975-00018	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
Com	nononto			
	ponents:			
Riba				
Rema	arks	:	No data availab	le
Germ	n cell mutagenicity			
Susp	ected of causing gene	tic defe	cts.	
<u>Com</u>	ponents:			
Sucr	ose:			
Geno	otoxicity in vitro		Test Type: In vi Result: negative	tro mammalian cell gene mutation test e
Riba	virin:			
Geno	otoxicity in vitro		Test Type: Bac Result: negative	terial reverse mutation assay (AMES) e
		-	Test Type: In vi Test system: R Result: positive	
		-		omosomal aberration uman lymphocytes e
Geno	otoxicity in vivo	:	Test Type: dom Species: Rat Result: negative	inant lethal test
		:	Test Type: Mou Species: Mouse Result: positive	9
		:	Test Type: Mici Species: Mouse Result: positive	9
	n cell mutagenicity - ssment		Positive result(s genicity tests.	s) from in vivo mammalian somatic cell muta
Carc	inogenicity			
Not c	lassified based on ava	ailable ir	formation.	
Com	ponents:			
Riba	virin:			
0	• • •		10.000	

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	6 Months
LOAEL	:	75 mg/kg body weight
Result	:	negative
Target Organs	:	Blood, Testes



according to the Globally Harmonized System

ersion 3	Revision Date: 30.09.2023	SDS Number: 406975-00018	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
Rema	arks	: The mechanis mans.	m or mode of action may not be relevant in h
	cation Route sure time EL It	 Rat Oral 2 Years 10 mg/kg body negative The mechanist mans. 	v weight m or mode of action may not be relevant in h
	cation Route sure time It	 Mouse Oral 18 Months negative The mechanist mans. 	m or mode of action may not be relevant in h
-	oductive toxicity	hild. Suspected of dam	aging fertility.
-	-		
Com	ponents:		
<u>Com</u> Ribay	ponents:	: Test Type: Fer Species: Rat, I Application Ro	tility male ute: Intraperitoneal injection L: < 20 mg/kg body weight educed fertility
<u>Com</u> Ribay	ponents: virin:	: Test Type: Fer Species: Rat, r Application Ro Fertility: LOAE Symptoms: Re Result: positive Test Type: Fer Species: Mous Application Ro	tility male oute: Intraperitoneal injection L: < 20 mg/kg body weight educed fertility e tility se, male oute: Oral L: 35 mg/kg body weight educed fertility
<u>Com</u> Ribay	ponents: virin:	 Test Type: Fer Species: Rat, I Application Ro Fertility: LOAE Symptoms: Re Result: positive Test Type: Fer Species: Mous Application Ro Fertility: LOAE Symptoms: Re Result: positive Test Type: Fer Species: Rat, f Application Ro Fertility: NOAE 	rtility male oute: Intraperitoneal injection L: < 20 mg/kg body weight educed fertility e rtility se, male oute: Oral L: 35 mg/kg body weight educed fertility e rtility
<u>Com</u> Ribay	ponents: virin:	 Test Type: Fer Species: Rat, i Application Ro Fertility: LOAE Symptoms: Re Result: positive Test Type: Fer Species: Mous Application Ro Fertility: LOAE Symptoms: Re Result: positive Test Type: Fer Species: Rat, i Application Ro Fertility: NOAE Result: Animal Test Type: Fer Species: Rat, i Application Ro Fertility: NOAE 	tility male oute: Intraperitoneal injection L: < 20 mg/kg body weight educed fertility e tility se, male oute: Oral L: 35 mg/kg body weight educed fertility e tility females oute: Oral EL: 10 mg/kg body weight testing did not show any effects on fertility.

according to the Globally Harmonized System



Version 2.8	Revision Date: 30.09.2023		DS Number: 06975-00018	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
ment			Symptoms: Redu fetuses, Skeletal	e: Oral oxicity: LOAEL: <= 1 mg/kg body weight iced body weight, Reduced number of viable malformations ixic effects and adverse effects on the off-
			Developmental T Symptoms: Redu	female e: Oral Maternal: LOAEL: 1 mg/kg body weight oxicity: LOAEL: 1 mg/kg body weight iced body weight, Skeletal malformations oxic effects and adverse effects on the off-
			Symptoms: Skele / resorption rate	r e: Oral oxicity: LOAEL: 2.5 mg/kg body weight etal and visceral variations, Total Resorptions exic effects and adverse effects on the off-
			Species: Rat Application Route General Toxicity Embryo-foetal tox	yo-foetal development e: Oral Maternal: NOAEL: 0.3 mg/kg body weight kicity: LOAEL: 1 mg/kg body weight etal malformations
Repro sessn	oductive toxicity - As- nent	:	fertility, based on	of adverse effects on sexual function and animal experiments., Clear evidence of ad- development, based on animal experiments.
	- single exposure assified based on availa	able	information.	
<u>Comp</u>	oonents:			
Ribay				
Asses	ssment	:	May cause respir	atory irritation.
	- repeated exposure ause damage to organs	s (B	lood) through prolo	nged or repeated exposure if swallowed.
	oonents:	``	, , , , , , ,	- · ·
Ribay	virin:			
Expos	sure routes t Organs	:	Ingestion Blood	

Eye contact

Ingestion



according to the Globally Harmonized System

Ribavirin Liquid Formulation

Version 2.8	Revision Date: 30.09.2023	SDS Number: 406975-00018	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
Asse	essment	: Causes dam exposure.	age to organs through prolonged or repeated
Repe	eated dose toxicity		
<u>Com</u>	ponents:		
Riba	virin:		
		: Monkey : 30 mg/kg : 10 d : Blood, Gastr	ointestinal tract
Expo		: Rat : 7.6 mg/kg : Inhalation : 90 d : Blood, Lungs	3
Expo		: Dog : 5 mg/kg : Oral : 1 yr : Blood, Gastr	ointestinal tract
Expo		: Mouse : 20 mg/kg : Oral : 18 Months : Blood, Cardi	o-vascular system
-	ration toxicity classified based on ava	ilable information.	
Expe	erience with human e	xposure	
<u>Com</u>	ponents:		
Riba	virin:		
Inhal	ation		Headache, Dizziness
Skin	contact	: Remarks: Ma	ased on Human Evidence ay cause eye irritation. Iman Evidence
Eve	oontoot		

: Remarks: May cause eye irritation. Based on Human Evidence

Symptoms: blood effects, immune system effects, anorexia, Dizziness, insomnia, Fatigue, Headache, Itching, Rash, liver

function change, Gastrointestinal disturbance

:



according to the Globally Harmonized System

Ribavirin Liquid Formulation

Version 2.8	Revision Date: 30.09.2023		S Number: 6975-00018	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
40.500				
12. ECOI	LOGICAL INFORMAT	ION		
Eco	toxicity			
Com	nponents:			
Riba	avirin:			
Toxi	city to fish	:	LC50 (Oncorh Exposure time	ynchus mykiss (rainbow trout)): > 119 mg/l : 96 h
	city to daphnia and oth atic invertebrates	ier :	Exposure time	a magna (Water flea)): > 117 mg/l : 48 h D Test Guideline 202
Tavi	oitu to olgoo/oguotio		ECEO (Decud	akirahaarialla ayhaanitata (araan alaaa))ya 110

Toxicity to algae/aquatic plants	quatic :	EC50 (Pseudokirchneriella subcapitata (green algae)): > 119 mg/l Exposure time: 96 h
		Method: OECD Test Guideline 201
		NOEC (Recude kirch parialla subaspitate (groop algoe)); 6.0

NOEC (Pseudokirchneriella subcapitata (green algae)): 6.9
mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

Persistence and degradability

No data available

Bioaccumulative potential

Components:

Sucrose:

Partition coefficient: n-	:	Pow: < 1
octanol/water		

Ribavirin:

Partition coefficient: n-	:	log Pow: 0.971
octanol/water		

Mobility in soil

No data available

Other adverse effects

No data available

according to the Globally Harmonized System



Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.8	30.09.2023	406975-00018	Date of first issue: 10.12.2015

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues	:	Do not dispose of waste into sewer.
		Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION

Revision Date	:	30.09.2023		
Further information				
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/		
Date format	:	dd.mm.yyyy		
Full text of other abbreviations				
ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)		

according to the Globally Harmonized System



Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.8	30.09.2023	406975-00018	Date of first issue: 10.12.2015

ACGIH / TWA

8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level: NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN